Reata neuromuscular disorder drug meets study endpoint, stock halted
Reata Pharmaceuticals Inc.
shares surged after hours Monday as the biotech company announced positive results from a clinical trial for a neuromuscular disorder treatment. Reata shares, which had been halted after hours, surged 33% in the extended session, after closing up 5% at $100.59 in Monday trading for a market cap of just over $3 billion.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
The 30-Second Trick to Making Garlic Extra-GarlickyThe flavor you get with this technique isn't just good—it's grate.
Weiterlesen »
This Expert's 30-Minute Walking Glute Workout Tones Your Butt in Ways Regular Walking Just Can'tJust walking won't work your glutes, this expert says. Instead, combine walking with bodyweight moves. Here's a 30-minute walking workout to start!
Weiterlesen »
UK Tech 100: The 30 most important, interesting, and impactful women shaping British technology in 2019Here are top female investors, founders, journalists, social media stars, and engineers in the UK tech sector today.
Weiterlesen »
Lizzie McGuire Will Return to TV as a 30-Year-Old Millennial in New YorkI must have missed this news back in August, but the upcoming Disney+ streaming service is planning to air a Lizzie McGuire reboot. I previously had no plans to get Disney+, but now that I know this, I may have to reconsider. This is how they get you.
Weiterlesen »